STOCKHOLM - August 26, 2026 - Inify Laboratories, a unique laboratory service
that provides diagnostics within pathology, is now operational in the UK,
marking a major milestone in the company's international expansion. Following
the completion of its UK laboratory and regulatory approval from the Care
Quality Commission (CQC), Inify has signed its first agreement with an NHS Trust
and commenced delivery of its digital pathology services.
The agreement with University Hospital Plymouth NHS Trust (UHP), signed in June,
represents an important entry point into the UK public healthcare system. The
collaboration focuses on streamlining diagnostics, shortening lead times and
improving patient pathways. The first patient samples were received at the end
of June.
"Successful launch means we have built the infrastructure, secured regulatory
approval, signed our first agreement and delivered our first services to the
NHS. This is only the start of Inify's international journey and gives us a
strong platform from which to grow," says Fredrik Palm, CEO of Inify.
In dialogue with many regions and hospitals
Under the agreement, Inify manages the full chain from logistics and sample
preparation to digitisation of patient samples. The hospital's pathologists can
then perform diagnostics remotely in Inify's digital pathology system. Initial
sample volumes are limited but are expected to increase gradually.
"The first delivery is an important proof point, but the real opportunity lies
ahead. We are in dialogue with additional regions and hospitals, and our first
NHS agreement gives us a strong reference as we continue to build our presence
across the UK," says Palm.
The UK laboratory has undergone an extensive review and received CQC approval, a
key requirement for conducting routine clinical diagnostics within the UK
healthcare system. Inify has also strengthened its UK organisation with the
appointment of an experienced Laboratory Director and additional Biomedical
Scientists.
Inify's model fits the NHS perfectly
Inify continues to focus on the NHS, which handles the vast majority of patients
undergoing prostate cancer investigations in the UK. Study visits to the
laboratory and participation in leading industry events are also supporting the
company's dialogue with potential customers and key stakeholders.
"We see a clear and significant need for more efficient pathology services in
the UK. Our ambition is to combine high-quality diagnostics with logistics,
digitisation and technology to create more efficient patient pathways. We are
convinced that our services have the potential to deliver meaningful value to
both healthcare providers and patients," says Palm.
Continued sales growth in Sweden
The UK expansion builds on Inify's established position in Sweden, where sales
continue to grow. During the second quarter, the company was awarded a tender
with Region Jämtland Härjedalen for complete prostate cancer diagnostics and
signed an evaluation agreement with Region Västmanland for gastrointestinal
diagnostics.
With regulatory approvals, operational infrastructure and its first NHS delivery
now in place, Inify enters the next phase of its international growth journey -
with the UK as a key market for future expansion.
For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com
###
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
###
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - - from logistics to
tissue preparation and diagnosis - - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)
oduct/equities/SE0017486103\
-MERK) under the ticker\
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)\